drugset / Trial / NCT02341391
Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis
RandomizedParallel-groupSingle-blindTreatment
Summary
The primary purpose of the this study is to evaluate the safety of TissueGene-C, a gene therapy product that uses allogenic human chondrocytes expressing Transforming Growth Factor(TGF)-β1 by assessing the inflammation at the injection site, the incidence and severity of the adverse events, the physical examination findings, and the laboratory test results after the intra-articular injection of TissueGene-C. And Secondary purpose is to evaluate the biological efficacy (knee pain, range of motion, functional tests, and MRI) of TissueGene-C and the distribution of TissueGene-C outside the injection site.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-08
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TissueGene-C | Cell therapy | 3e+06 cells | Other |
| Subject | TissueGene-C | Cell therapy | 1e+07 cells | Other |
| Subject | TissueGene-C | Cell therapy | 3e+07 cells | Other |